Benitec’s BB-301 Shows Durable Efficacy in OPMD Trial
Event summary
- All four patients in Cohort 1 of Benitec’s BB-301 Phase 1b/2a trial met responder criteria at 12 months, showing durable efficacy.
- Patient 1 demonstrated deepening improvements in dysphagia symptoms at 24 months post-treatment.
- First patient in Cohort 2 treated with higher-dose BB-301 in Q4 2025; interim results expected mid-2026.
- FDA meeting to finalize pivotal study design planned for mid-2026.
- Q2 2026 financials: $13.4M in expenses, $189M in cash reserves.
The big picture
Benitec’s positive Phase 1b/2a data for BB-301 reinforces the potential of gene therapy in rare genetic disorders like OPMD. The durable efficacy signals could position Benitec as a key player in the RNA interference space, though execution risks remain high given the clinical-stage nature of its pipeline.
What we're watching
- Regulatory Pathway
- Whether the FDA meeting mid-2026 will confirm a streamlined path to approval for BB-301.
- Dose Optimization
- How Cohort 2’s higher-dose results compare to Cohort 1’s efficacy and safety profile.
- Cash Runway
- The pace at which Benitec burns through its $189M cash reserves as it advances BB-301.
Related topics